Author

Lorraine A. Soisson

Observed names: L A Soisson, L.A. Soisson, Lorraine A Soisson, Lorraine Soisson, Soisson Lorraine, Soisson, Lorraine

Institution: United States Agency for International Development

Observed institutions: Johns Hopkins University, Johns Hopkins Medicine, United States Agency for International Development

OpenAlex ID: A5000754492

A Field Trial to Assess a Blood-Stage Malaria Vaccine

2011 · Mahamadou A. Thera, Ogobara K. Doumbo, et al. · New England Journal of Medicine · 376

Blood Stage Malaria Vaccine Eliciting High Antigen-Specific Antibody Concentrations Confers No Protection to Young Children in Western Kenya

2009 · Bernhards R. Ogutu, Odika J. Apollo, et al. · PLoS ONE · 344

PDF

Phase 1/2a Study of the Malaria Vaccine Candidate Apical Membrane Antigen-1 (AMA-1) Administered in Adjuvant System AS01B or AS02A

2009 · Michele D. Spring, James F. Cummings, et al. · PLoS ONE · 206

PDF

Safety and Immunogenicity of an AMA-1 Malaria Vaccine in Malian Adults: Results of a Phase 1 Randomized Controlled Trial

2008 · Mahamadou A. Thera, Ogobara K. Doumbo, et al. · PLoS ONE · 176

PDF

Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination

2021 · Angela M. Minassian, Sarah E. Silk, et al. · Med · 146

PDF

DNA Prime/Adenovirus Boost Malaria Vaccine Encoding P. falciparum CSP and AMA1 Induces Sterile Protection Associated with Cell-Mediated Immunity

2013 · Ilin Chuang, Martha Sedegah, et al. · PLoS ONE · 141

PDF

Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01

2016 · Ruth O. Payne, Kathryn H. Milne, et al. · The Journal of Infectious Diseases · 113

PDF

Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya

2005 · José A. Stoute, Joash Gombe, et al. · Vaccine · 100

Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research

2007 · Mark E. Polhemus, Alan J. Magill, et al. · Vaccine · 99

Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine☆

2005 · Christian F. Ockenhouse, Evelina Angov, et al. · Vaccine · 94

High Antibody Titer against Apical Membrane Antigen-1 Is Required to Protect against Malaria in the Aotus Model

2009 · Sheetij Dutta, JoAnn S. Sullivan, et al. · PLoS ONE · 93

PDF

Molecular Basis of Allele-Specific Efficacy of a Blood-Stage Malaria Vaccine: Vaccine Development Implications

2012 · Amed Ouattara, Shannon Takala-Harrison, et al. · The Journal of Infectious Diseases · 91

PDF

Adenovirus-5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part B: Safety, Immunogenicity and Protective Efficacy of the CSP Component

2011 · Cindy Tamminga, Martha Sedegah, et al. · PLoS ONE · 80

PDF

Protective immunity in baboons vaccinated with a recombinant antigen or radiation-attenuated cercariae of Schistosoma mansoni is antibody-dependent.

1993 · L A Soisson, G D F Reid, et al. · The Journal of Immunology · 75

Safety and Allele-Specific Immunogenicity of a Malaria Vaccine in Malian Adults: Results of a Phase I Randomized Trial

2006 · Mahamadou A Thera, Ogobara K Doumbo, et al. · PLoS Clinical Trials · 73

PDF

Adenovirus 5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part A: Safety and Immunogenicity in Seronegative Adults

2011 · Martha Sedegah, Cindy Tamminga, et al. · PLoS ONE · 69

PDF

A malaria vaccine protects Aotus monkeys against virulent Plasmodium falciparum infection

2017 · Prakash Srinivasan, G. Christian Baldeviano, et al. · npj Vaccines · 65

PDF

Safety and Reactogenicity of an MSP-1 Malaria Vaccine Candidate: A Randomized Phase Ib Dose-Escalation Trial in Kenyan Children

2006 · Mark R Withers, Denise McKinney, et al. · PLoS Clinical Trials · 64

PDF

Sterile Immunity to Malaria after DNA Prime/Adenovirus Boost Immunization Is Associated with Effector Memory CD8+T Cells Targeting AMA1 Class I Epitopes

2014 · Martha Sedegah, Michael R. Hollingdale, et al. · PLoS ONE · 61

PDF

Safety and Immunogenicity of an AMA1 Malaria Vaccine in Malian Children: Results of a Phase 1 Randomized Controlled Trial

2010 · Mahamadou A. Thera, Ogobara K. Doumbo, et al. · PLoS ONE · 57

PDF

Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stagePlasmodium falciparumDNA vaccine combined with escalating dose human GM-CSF DNA

2012 · Thomas L. Richie, Yupin Charoenvit, et al. · Human Vaccines & Immunotherapeutics · 48

A multilateral effort to develop DNA vaccines against falciparum malaria

2002 · Sanjai Kumar, Judith E Epstein, et al. · Trends in Parasitology · 46

Extended Safety, Immunogenicity and Efficacy of a Blood-Stage Malaria Vaccine in Malian Children: 24-Month Follow-Up of a Randomized, Double-Blinded Phase 2 Trial

2013 · Matthew B. Laurens, Mahamadou A. Thera, et al. · PLoS ONE · 45

Identification of minimal human MHC-restricted CD8+ T-cell epitopes within the Plasmodium falciparum circumsporozoite protein (CSP)

2013 · Martha Sedegah, Yohan Kim, et al. · Malaria Journal · 41

PDF

Human adenovirus 5-vectoredPlasmodium falciparumNMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection

2013 · Cindy Tamminga, Martha Sedegah, et al. · Human Vaccines & Immunotherapeutics · 39

PDF

Works count: 68

Citation count: 3,052

H-index: 28

I10-index: 38